Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3330)
All Articles published online
|
Sep 7, 2007 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Baradari V, Höpfner M, Huether A, Schuppan D, Scherübl H. Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol 2007; 13(33): 4458-4466 [PMID: 17724801 DOI: 10.3748/wjg.v13.i33.4458] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i33/4458.htm |
| Number | Citing Articles |
| 1 |
Taranom Mobasheri, Elham Rayzan, Mahsima Shabani, Mina Hosseini, Ghanbar Mahmoodi Chalbatani, Nima Rezaei. Neuroblastoma‐targeted nanoparticles and novel nanotechnology‐based treatment methods. Journal of Cellular Physiology 2021; 236(3): 1751 doi: 10.1002/jcp.29979
|
| 2 |
Christopher Alan Rokes, Mark Remke, Nandita Guha-Thakurta, Olaf Witt, Andrey Korshunov, Stephan Pfister, Johannes E. Wolff. Sorafenib Plus Valproic Acid for Infant Spinal Glioblastoma. Journal of Pediatric Hematology/Oncology 2010; 32(6): 511 doi: 10.1097/MPH.0b013e3181d74702
|
| 3 |
Nuttapong Ngamphaiboon, Grace K. Dy, Wen Wee Ma, Yujie Zhao, Thanyanan Reungwetwattana, Dawn DePaolo, Yi Ding, William Brady, Gerald Fetterly, Alex A. Adjei. A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors. Investigational New Drugs 2015; 33(1): 225 doi: 10.1007/s10637-014-0174-6
|
| 4 |
Faria Sultana, Kesari Lakshmi Manasa, Siddiq Pasha Shaik, Srinivasa Reddy Bonam, Ahmed Kamal. Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update. Current Medicinal Chemistry 2020; 26(40): 7212 doi: 10.2174/0929867325666180530094120
|
| 5 |
John Chen, Hui‑Yen Chuang, Yi‑Jen Liao, Fei‑Ting Hsu, Yen‑Chung Chen, Wei‑Hsun Wang, Jeng‑Jong Hwang. Enhanced cytotoxicity of human hepatocellular carcinoma cells following pretreatment with sorafenib combined with trichostatin A. Oncology Letters 2018; doi: 10.3892/ol.2018.9582
|
| 6 |
Luca Maroni, Marco Marzioni. Diagnosis and Management of Cholangiocarcinoma. 2021; : 555 doi: 10.1007/978-3-030-70936-5_26
|
| 7 |
Li-Ning Xu, Xin Wang, Sheng-Quan Zou. Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines. World Journal of Gastroenterology 2008; 14(16): 2578-2581 doi: 10.3748/wjg.14.2578
|
| 8 |
Michael Höpfner, Detlef Schuppan, Hans Scherübl. Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: Recent advances and future perspectives. World Journal of Gastroenterology 2008; 14(16): 2461-2473 doi: 10.3748/wjg.14.2461
|
| 9 |
Michael Höpfner, Detlef Schuppan, Hans Scherübl. Targeted medical therapy of biliary tract cancer: Recent advances and future perspectives. World Journal of Gastroenterology 2008; 14(46): 7021-7032 doi: 10.3748/wjg.14.7021
|
| 10 |
Masumeh Sanaei, Fraidoon Kavoosi. Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers. Advanced Biomedical Research 2019; 8(1): 63 doi: 10.4103/abr.abr_142_19
|
| 11 |
Da-long Yin, Ying-jian Liang, Tong-sen Zheng, Rui-peng Song, Jia-bei Wang, Bo-shi Sun, Shang-ha Pan, Lian-dong Qu, Jia-ren Liu, Hong-chi Jiang, Lian-xin Liu. EF24 inhibits tumor growth and metastasis via suppressing NF-kappaB dependent pathways in human cholangiocarcinoma. Scientific Reports 2016; 6(1) doi: 10.1038/srep32167
|
| 12 |
Steffen Wedel, Lukasz Hudak, Jens‐Michael Seibel, Eva Juengel, Elsie Oppermann, Axel Haferkamp, Roman A. Blaheta. Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer. The Prostate 2011; 71(7): 722 doi: 10.1002/pros.21288
|
| 13 |
Sumera Rizvi, Shahid A. Khan, Christopher L. Hallemeier, Robin K. Kelley, Gregory J. Gores. Cholangiocarcinoma — evolving concepts and therapeutic strategies. Nature Reviews Clinical Oncology 2018; 15(2): 95 doi: 10.1038/nrclinonc.2017.157
|
| 14 |
Junyao Xu, Jennifer J. Knox, Emin Ibrahimov, Eric Chen, Stefano Serra, Ming Tsao, Pinjiang Cao, Douglass Vines, David E. Green, Cristiane Metran-Nascente, Mairead G. McNamara, David W. Hedley. Sequence Dependence of MEK Inhibitor AZD6244 Combined with Gemcitabine for the Treatment of Biliary Cancer. Clinical Cancer Research 2013; 19(1): 118 doi: 10.1158/1078-0432.CCR-12-2557
|
| 15 |
Vikrant Rai, Chandra Boosani, Devendra Agrawal. The promising role of epigenetic mediators and microRNAs in the early diagnosis of cholangiocarcinoma (Review). World Academy of Sciences Journal 2019; doi: 10.3892/wasj.2019.18
|
| 16 |
Magdalena Rogalska-Taranta, Jesper B. Andersen. Involvement of Epigenomic Factors in Bile Duct Cancer. Seminars in Liver Disease 2022; 42(02): 202 doi: 10.1055/s-0042-1748188
|
| 17 |
Stefan Vallo, Jens Mani, Matthias Stastny, Jasmina Makarević, Eva Juengel, Igor Tsaur, Georg Bartsch, Axel Haferkamp, Roman A. Blaheta. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258. Investigational New Drugs 2013; 31(2): 265 doi: 10.1007/s10637-012-9851-5
|
| 18 |
Colm J. O’Rourke, Letizia Satriano, Douglas V.N.P. Oliveira, Patricia Munoz-Garrido, Jesper B. Andersen. Pharmacoepigenetics. 2019; : 551 doi: 10.1016/B978-0-12-813939-4.00017-6
|
| 19 |
Constantine S. Mitsiades, Teru Hideshima, Dharminder Chauhan, Douglas W. McMillin, Steffen Klippel, Jacob P. Laubach, Nikhil C. Munshi, Kenneth C. Anderson, Paul G. Richardson. Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib. Seminars in Hematology 2009; 46(2): 166 doi: 10.1053/j.seminhematol.2009.02.003
|
| 20 |
Aikaterini Mastoraki, Dimitrios Schizas, Nikolaos Charalampakis, Leon Naar, Maria Ioannidi, Diamantis Tsilimigras, Maria Sotiropoulou, Dimitrios Moris, Pantelis Vassiliu, Evangelos Felekouras. Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma. Molecular Diagnosis & Therapy 2020; 24(2): 175 doi: 10.1007/s40291-020-00454-x
|
| 21 |
Ranu S Sinniah, Mark S Shapses, Mohammad Umar Ahmed, Hani Babiker, Sreenivasa R. Chandana. Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1. Expert Opinion on Investigational Drugs 2021; 30(10): 1047 doi: 10.1080/13543784.2021.1985461
|
| 22 |
Wen Hui Lin, Janet L. Martin, Deborah J. Marsh, Michelle M. Jack, Robert C. Baxter. Involvement of Insulin-like Growth Factor-binding Protein-3 in the Effects of Histone Deacetylase Inhibitor MS-275 in Hepatoma Cells. Journal of Biological Chemistry 2011; 286(34): 29540 doi: 10.1074/jbc.M111.263111
|
| 23 |
Jacob Schmidt, Weronika Kuzyniak, Janine Berkholz, Gustav Steinemann, Racheal Ogbodu, Bj�rn Hoffmann, Geraldine Nouailles, Ayşe G�rek, Bianca Nitzsche, Michael H�pfner. Novel zinc‑ and silicon‑phthalocyanines as photosensitizers for photodynamic therapy of cholangiocarcinoma. International Journal of Molecular Medicine 2018; doi: 10.3892/ijmm.2018.3620
|
| 24 |
Marcus Wiedmann, Helmut Witzigmann, Joachim Mössner. Clinical Hepatology. 2010; : 1519 doi: 10.1007/978-3-642-04519-6_62
|
| 25 |
Colm J. O'Rourke, Patricia Munoz-Garrido, Esmeralda L. Aguayo, Jesper B. Andersen. Epigenome dysregulation in cholangiocarcinoma. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018; 1864(4): 1423 doi: 10.1016/j.bbadis.2017.06.014
|
| 26 |
Marta Bombardo, Enrica Saponara, Ermanno Malagola, Rong Chen, Gitta M Seleznik, Cecile Haumaitre, Evans Quilichini, Anja Zabel, Theresia Reding, Rolf Graf, Sabrina Sonda. Class I histone deacetylase inhibition improves pancreatitis outcome by limiting leukocyte recruitment and acinar‐to‐ductal metaplasia. British Journal of Pharmacology 2017; 174(21): 3865 doi: 10.1111/bph.13984
|
| 27 |
Thorsten Lieke, Wolf Ramackers, Sabine Bergmann, Jürgen Klempnauer, Michael Winkler, Johannes Klose. Impact of Salinomycin on human cholangiocarcinoma: induction of apoptosis and impairment of tumor cell proliferation in vitro
. BMC Cancer 2012; 12(1) doi: 10.1186/1471-2407-12-466
|
| 28 |
Kulthida Vaeteewoottacharn, Ryusho Kariya, Kouki Matsuda, Manabu Taura, Chaisiri Wongkham, Sopit Wongkham, Seiji Okada. Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma. Journal of Cancer Research and Clinical Oncology 2013; 139(9): 1551 doi: 10.1007/s00432-013-1473-6
|
| 29 |
Crystal S. Denlinger, Neal J. Meropol, Tianyu Li, Nancy L. Lewis, Paul F. Engstrom, Louis M. Weiner, Jonathan D. Cheng, R. Katherine Alpaugh, Harry Cooper, John J. Wright, Steven J. Cohen. A Phase II Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Biliary Tract Cancers. Clinical Colorectal Cancer 2014; 13(2): 81 doi: 10.1016/j.clcc.2013.12.005
|
| 30 |
Baiyin Zhong, Qicheng Liao, Xin Wang, Xiaonong Wang, Jianhong Zhang. The roles of epigenetic regulation in cholangiocarcinogenesis. Biomedicine & Pharmacotherapy 2023; 166: 115290 doi: 10.1016/j.biopha.2023.115290
|
| 31 |
Giuseppe Tonini, Vladimir Virzì, Maria Elisabetta Fratto, Bruno Vincenzi, Daniele Santini. Targeted therapy in biliary tract cancer: 2009 update. Future Oncology 2009; 5(10): 1675 doi: 10.2217/fon.09.130
|
| 32 |
Jeffrey Knipstein, Lia Gore. Entinostat for treatment of solid tumors and hematologic malignancies. Expert Opinion on Investigational Drugs 2011; 20(10): 1455 doi: 10.1517/13543784.2011.613822
|
| 33 |
Münevver Yenigül, Emel Başak Gencer Akçok. Histone Deacetylase Inhibition and Autophagy Modulation Induces a Synergistic Antiproliferative Effect and Cell Death in Cholangiocarcinoma Cells. ACS Omega 2023; 8(24): 21755 doi: 10.1021/acsomega.3c01317
|
| 34 |
Zdeněk Kejík, Milan Jakubek, Robert Kaplánek, Jarmila Králová, Ivan Mikula, Pavel Martásek, Vladimír Král. Epigenetic agents in combined anticancer therapy. Future Medicinal Chemistry 2018; 10(9): 1113 doi: 10.4155/fmc-2017-0203
|
| 35 |
T Hideshima, R Mazitschek, L Santo, N Mimura, G Gorgun, P G Richardson, N Raje, K C Anderson. Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors. Leukemia 2014; 28(2): 457 doi: 10.1038/leu.2013.301
|
| 36 |
Chiara Braconi, Erica Swenson, Takayuki Kogure, Nianyuan Huang, Tushar Patel, Xin Wei Wang. Targeting the IL-6 Dependent Phenotype Can Identify Novel Therapies for Cholangiocarcinoma. PLoS ONE 2010; 5(12): e15195 doi: 10.1371/journal.pone.0015195
|
| 37 |
Paul Dent, David T. Curiel, Paul B. Fisher, Steven Grant. Synergistic combinations of signaling pathway inhibitors: Mechanisms for improved cancer therapy. Drug Resistance Updates 2009; 12(3): 65 doi: 10.1016/j.drup.2009.03.001
|
| 38 |
Loredana Cappellacci, Diego R. Perinelli, Filippo Maggi, Mario Grifantini, Riccardo Petrelli. Recent Progress in Histone Deacetylase Inhibitors as Anticancer Agents. Current Medicinal Chemistry 2020; 27(15): 2449 doi: 10.2174/0929867325666181016163110
|
| 39 |
Dawoon E. Jung, Soo Been Park, Kahee Kim, Chanyang Kim, Si Young Song. CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-11094-3
|
| 40 |
Christian Mayr, Tobias Kiesslich, Sara Erber, Dino Bekric, Heidemarie Dobias, Marlena Beyreis, Markus Ritter, Tarkan Jäger, Bettina Neumayer, Paul Winkelmann, Eckhard Klieser, Daniel Neureiter. HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer. Cancers 2021; 13(15): 3862 doi: 10.3390/cancers13153862
|
| 41 |
K Ted Thurn, Scott Thomas, Amy Moore, Pamela N Munster. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncology 2011; 7(2): 263 doi: 10.2217/fon.11.2
|
| 42 |
Michael Höpfner, Detlef Schuppan, Hans Scherübl. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World Journal of Gastroenterology 2008; 14(1): 1-14 doi: 10.3748/wjg.14.1
|